Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
Fiche publication
Date publication
mai 2017
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AVEROUS Gerlinde, Mr MONNIEN Franck, Pr BIBEAU Frédéric
Tous les auteurs :
Valmary-Degano S, Colpart P, Villeneuve L, Monnien F, M'Hamdi L, Lang Averous G, Capovilla M, Bibeau F, Laverriere MH, Verriele-Beurrier V, Ben Rejeb H, Dartigues P, Hommell-Fontaine J, Gilly FN, Isaac S, Mery E,
Lien Pubmed
Résumé
Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM.
Mots clés
Epithelioid subtype, Immunohistochemistry, PD-L1, Peritoneal mesothelioma, Survival
Référence
Eur J Surg Oncol. 2017 May;: